Bifogade filer
Announcement 261 - Adjustment of 2023-24 guidance
Kurs
-21,67%
Likviditet
397 MDKK
Kalender
| Tid* | ||
| 2025-10-09 | N/A | Årsstämma |
| 2025-09-11 | 08:00 | Bokslutskommuniké 2025 |
| 2025-02-05 | 17:00 | Kvartalsrapport 2025-Q2 |
| 2024-10-11 | - | X-dag ordinarie utdelning CHEMM 4.00 DKK |
| 2024-10-10 | - | Årsstämma |
| 2024-09-11 | - | Bokslutskommuniké 2024 |
| 2024-02-05 | - | Kvartalsrapport 2024-Q2 |
| 2023-10-13 | - | X-dag ordinarie utdelning CHEMM 6.00 DKK |
| 2023-10-12 | - | Årsstämma |
| 2023-09-14 | - | Bokslutskommuniké 2023 |
| 2023-05-09 | - | 15-10 2023-Q3 |
| 2023-02-09 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-14 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2022-10-13 | - | Årsstämma |
| 2022-09-15 | - | Bokslutskommuniké 2022 |
| 2022-02-08 | - | Kvartalsrapport 2022-Q2 |
| 2021-10-15 | - | X-dag ordinarie utdelning CHEMM 4.00 DKK |
| 2021-10-14 | - | Årsstämma |
| 2021-09-16 | - | Bokslutskommuniké 2021 |
| 2021-02-05 | - | Kvartalsrapport 2021-Q2 |
| 2020-10-09 | - | X-dag ordinarie utdelning CHEMM 1.50 DKK |
| 2020-10-08 | - | Årsstämma |
| 2020-09-17 | - | Bokslutskommuniké 2020 |
| 2020-02-07 | - | Kvartalsrapport 2020-Q2 |
| 2020-01-14 | - | X-dag bonusutdelning CHEMM 13 |
| 2020-01-13 | - | Extra Bolagsstämma 2020 |
| 2019-10-11 | - | X-dag ordinarie utdelning CHEMM 7.50 DKK |
| 2019-10-10 | - | Årsstämma |
| 2019-09-17 | - | Bokslutskommuniké 2019 |
| 2019-02-08 | - | Kvartalsrapport 2019-Q2 |
| 2018-10-12 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2018-10-11 | - | Årsstämma |
| 2018-09-18 | - | Bokslutskommuniké 2018 |
| 2018-02-09 | - | Kvartalsrapport 2018-Q2 |
| 2017-11-15 | - | Årsstämma |
| 2017-10-13 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2017-10-12 | - | Årsstämma |
| 2017-09-19 | - | Bokslutskommuniké 2017 |
| 2017-02-10 | - | Kvartalsrapport 2017-Q2 |
| 2016-10-14 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2016-10-13 | - | Årsstämma |
| 2016-09-20 | - | Bokslutskommuniké 2016 |
| 2016-02-26 | - | Kvartalsrapport 2016-Q2 |
| 2015-10-09 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2015-10-08 | - | Årsstämma |
| 2015-05-15 | - | Kvartalsrapport 2015-Q3 |
| 2014-10-10 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2014-10-09 | - | Årsstämma |
| 2014-05-15 | - | Kvartalsrapport 2014-Q3 |
| 2013-11-15 | - | Kvartalsrapport 2014-Q1 |
| 2013-10-11 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2013-10-10 | - | Årsstämma |
| 2013-07-25 | - | Extra Bolagsstämma 2013 |
| 2013-05-14 | - | Kvartalsrapport 2013-Q3 |
| 2012-11-14 | - | Kvartalsrapport 2013-Q1 |
| 2012-10-12 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2012-10-11 | - | Årsstämma |
| 2012-05-11 | - | Kvartalsrapport 2012-Q3 |
| 2011-11-11 | - | Kvartalsrapport 2012-Q1 |
| 2011-10-14 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2011-10-13 | - | Årsstämma |
| 2011-05-13 | - | Kvartalsrapport 2011-Q3 |
| 2010-11-12 | - | Kvartalsrapport 2011-Q1 |
| 2010-10-06 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
ANNOUNCEMENT NO. 261
Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year
According to the preliminary figures, revenue in the third quarter of 2023/24 was DKK 98.9 million and in the first nine months of 2023/24 DKK 298.2 million.
Based on the development in the third quarter of 2023/24 and the expectations for the remaining part of the financial year, expectations for revenue for the 2023/24 financial year are clarified. Hence, revenue in 2023/24 is expected to be in the DKK 400-415 million range against previously announced DKK 400-435 million and thus still within the most recently announced range.
Earnings in the third quarter of 2023/24 have been affected by one-off costs in connection with organizational changes, and, among other things, as a result of this, an operating result (EBITDA) of DKK 185-200 million is expected in 2023/24 against previously announced DKK 200-220 million.
Final figures for the third quarter 2023/24 and for the first nine months of 2023/24 will be included in the interim report for the third quarter 2023/24, which will be published on 8 May 2024.
For further information
Niels Høy Nielsen, CFO
Phone: (+45) 2551 8724
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com